ANTX
Price
$4.61Alerts
Change
+$0.28 (+6.47%)
Updated
Nov 11, 03:08 PM (EDT)
Capitalization
150.94M
140 days until earnings call
Intraday BUY SELL Signals
RNAC
Price
$6.87Alerts
Change
-$0.02 (-0.29%)
Updated
Nov 11, 02:55 PM (EDT)
Capitalization
227.82M
126 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANTX vs RNAC

ANTX vs RNAC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANTX vs. RNAC commentary
Nov 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANTX is a Hold and RNAC is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ANTX with price predictions
Nov 10, 2026

ANTX in +21.50% Uptrend, advancing for three consecutive days on October 29, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ANTX advanced for three days, in 199 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANTX's RSI Indicator exited the oversold zone, 15 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ANTX as a result. In 62 of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for ANTX just turned positive on October 27, 2026. Looking at past instances where ANTX's MACD turned positive, the stock continued to rise in 25 of 30 cases over the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 45 cases where ANTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

ANTX moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

ANTX broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ANTX entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.988) is normal, around the industry mean (3.498). P/E Ratio (-3.810) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ANTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for RNAC with price predictions
Nov 10, 2026

RNAC's RSI Indicator climbs out of oversold territory

The RSI Oscillator for RNAC moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 38 of the 43 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on RNAC as a result. In 66 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

The Moving Average Convergence Divergence (MACD) for RNAC just turned positive on October 21, 2026. Looking at past instances where RNAC's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.

Following a +7.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNAC advanced for three days, in 216 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 50 cases where RNAC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

RNAC moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for RNAC moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

RNAC broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RNAC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.819) is normal, around the industry mean (3.498). P/E Ratio (-1.303) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (144.928) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. RNAC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ANTX vs RNAC: Fundamental Ratings
ANTX
RNAC
OUTLOOK RATING
1..100
2810
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3970
P/E GROWTH RATING
1..100
2434
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RNAC's Valuation (27) in the Biotechnology industry is in the same range as ANTX (29) in the Managed Health Care industry. This means that RNAC’s stock grew similarly to ANTX’s over the last 12 months.

RNAC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ANTX (100) in the Managed Health Care industry. This means that RNAC’s stock grew similarly to ANTX’s over the last 12 months.

ANTX's SMR Rating (98) in the Managed Health Care industry is in the same range as RNAC (100) in the Biotechnology industry. This means that ANTX’s stock grew similarly to RNAC’s over the last 12 months.

ANTX's Price Growth Rating (39) in the Managed Health Care industry is in the same range as RNAC (70) in the Biotechnology industry. This means that ANTX’s stock grew similarly to RNAC’s over the last 12 months.

ANTX's P/E Growth Rating (24) in the Managed Health Care industry is in the same range as RNAC (34) in the Biotechnology industry. This means that ANTX’s stock grew similarly to RNAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANTXRNAC
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 14 days ago
84%
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
85%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 11, 2026
Stock price -- (ANTX: $4.33 vs. RNAC: $6.89)
Brand notoriety: ANTX and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANTX: 95% vs. RNAC: 66%
Market capitalization -- ANTX: $150.94M vs. RNAC: $227.82M
ANTX [@Biotechnology] is valued at $150.94M. RNAC’s [@Biotechnology] market capitalization is $227.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANTX’s FA Score shows that 2 FA rating(s) are green while RNAC’s FA Score has 1 green FA rating(s).

  • ANTX’s FA Score: 2 green, 3 red.
  • RNAC’s FA Score: 1 green, 4 red.
According to our system of comparison, ANTX is a better buy in the long-term than RNAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANTX’s TA Score shows that 4 TA indicator(s) are bullish while RNAC’s TA Score has 4 bullish TA indicator(s).

  • ANTX’s TA Score: 4 bullish, 5 bearish.
  • RNAC’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ANTX is a better buy in the short-term than RNAC.

Price Growth

ANTX (@Biotechnology) experienced а +3.59% price change this week, while RNAC (@Biotechnology) price change was +7.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.36%. For the same industry, the average monthly price growth was -9.96%, and the average quarterly price growth was +79.71%.

Reported Earning Dates

ANTX is expected to report earnings on Mar 31, 2027.

RNAC is expected to report earnings on Mar 17, 2027.

Industries' Descriptions

@Biotechnology (-0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ANTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANTX has been loosely correlated with DNTH. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANTX jumps, then DNTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANTX
1D Price
Change %
ANTX100%
+8.25%
DNTH - ANTX
40%
Loosely correlated
-1.32%
RLMD - ANTX
39%
Loosely correlated
+3.14%
XENE - ANTX
38%
Loosely correlated
+2.32%
SLDB - ANTX
34%
Loosely correlated
+2.14%
RNAC - ANTX
31%
Poorly correlated
-1.85%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FLJJ34.030.35
+1.05%
AllianzIM U.S. Equity 6 Month Floor5 Jan/Jul ETF (FLJJ)
MDLV32.000.06
+0.18%
Morgan Dempsey Large Cap Value ETF (MDLV)
DLN100.140.02
+0.02%
WisdomTree U.S. LargeCap Dividend Fund (DLN)
GRX10.37-0.23
-2.17%
Gabelli Healthcare & Wellness Trust (The)
SLVR47.58-2.71
-5.39%
Sprott Silver Miners & Physical Silver ETF (SLVR)